Get the Stockscreener App
2.1632
5.26%
-0.1168
Aldeyra Therapeutics Inc stock is traded at $2.1632, with a volume of 959.76K.
It is down -5.26% in the last 24 hours and down -18.49% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$2.28
Open:
$2.26
24h Volume:
959.76K
Relative Volume:
0.56
Market Cap:
$129.39M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-2.8843
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
-2.70%
1M Performance:
-18.49%
6M Performance:
-55.92%
1Y Performance:
-42.09%
1-Day Range:
$2.10
$2.26
1-Week Range:
$2.10
$2.30
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
2.1601 | 134.77M | 0 | -44.80M | -30.67M | -0.75 |
|
ONC
Beone Medicines Ltd Adr
|
246.64 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.63 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.57 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.51 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Trading (ALDX) With Integrated Risk Controls - news.stocktradersdaily.com
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference | ALDX Stock News - GuruFocus
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - Business Wire
Northern Trust Corp Purchases 16,894 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Acquired by Deutsche Bank AG - Defense World
D. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs - Defense World
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - Yahoo Finance
HC Wainwright Has Strong Forecast for ALDX FY2029 Earnings - Defense World
Q2 EPS Estimate for Aldeyra Therapeutics Lifted by Analyst - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Raised to “Sell” at StockNews.com - Defense World
Balyasny Asset Management L.P. Acquires New Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Given “Buy” Rating at HC Wainwright - Defense World
ALDX: HC Wainwright & Co. Reiterates Buy Rating with $10 Target | ALDX Stock News - GuruFocus
(ALDX) Trading Report - news.stocktradersdaily.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - FinancialContent
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock Holdings Lessened by Price T Rowe Associates Inc. MD - Defense World
Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune
Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire
Aldeyra Therapeutics, Inc. SEC 10-Q Report - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
Hsbc Holdings PLC Acquires Shares of 10,457 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Barclays PLC Has $376,000 Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, - GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm - TradingView
Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early - simplywall.st
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with - GlobeNewswire
Aldeyra makes third run at FDA approval for dry eye drug - The Pharma Letter
Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data - insights.citeline.com
Aldeyra DED phase III hits but reproxalap field goal fumbled - BioWorld MedTech
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline - Barchart.com
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Aldeyra plots third FDA filing for dry eye disease drug after latest Phase 3 data - Endpoints News
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Ey - GuruFocus
Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial - GuruFocus
Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial | ALDX Stock News - GuruFocus
Breakthrough in Dry Eye Treatment: Aldeyra's Reproxalap Achieves Significant Phase 3 Results, FDA Filing Next - Stock Titan
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap - Business Wire
ALDX SECURITIES ALERT: Lose Money on Aldeyra Therapeutics, - GlobeNewswire
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
Invesco Ltd. Cuts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) - GlobeNewswire
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Renaissance Technologies LLC Purchases 59,700 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Ongoing Securities Investigation - TradingView
Aldeyra Therapeutics Inc (ALDX) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aldeyra Therapeutics Inc Stock (ALDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Machatha Stephen | Chief Development Officer |
Aug 12 '24 |
Sale |
4.74 |
16,041 |
75,975 |
236,771 |
| Greenberg Bruce | See Remarks |
Aug 12 '24 |
Sale |
4.74 |
10,834 |
51,313 |
126,382 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):